Information Provided By: 
Fly News Breaks for November 6, 2017
RIGL
Nov 6, 2017 | 07:11 EDT
H.C. Wainwright analyst Joseph Pantginis assumed coverage of Rigel Pharmaceuticals with a Buy rating and $7 price target. The analyst projects FDA approval of fostamatinib for the treatment of immune thrombocytopenic purpura by the April 2018 action date. He also believes that a "significant upcoming potential driver" could be the signing of a major outside the U.S. partnership for the drug.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
